Navigation Links
LX211 highlighted as potential disease modifying therapy for non-infectious uveitis
Date:10/26/2009

ltimately to improved outcomes in this difficult-to-treat condition."

Results of the LX211-01 study, which investigated LX211 in 218 patients with active, sight-threatening uveitis affecting the posterior segment of the eye, will also be presented at AAO on Monday October 26 at 9:00 am PT by clinical investigator Quan D. Nguyen, M.D., of the Wilmer Eye Institute at The Johns Hopkins University, Baltimore, MD. "In this study, also a double-masked, placebo-controlled, dose-ranging trial conducted in North America, Europe and India, control of inflammation was evaluated by means of change in vitreous haze at weeks 16 and 24. Results showed the LX211 presumed label dose of 0.4 mg/kg twice daily to be statistically significantly superior to placebo at both time points. Preservation of vision was also demonstrated in this study."

In explaining the overall clinical benefit, C. Stephen Foster, MD, President, Massachusetts Eye Research and Surgery Institution (MERSI), highlighted the ability of LX211 to control inflammation and to significantly delay recurrence of inflammatory exacerbation compared to the control group. Moreover, this result was achieved while successfully reducing corticosteroids to 5 mg/day or less. "Therapy with LUVENIQ conforms to the 2000 uveitis treatment guidelines, and is supported by randomized clinical trials that offer the highest level of evidence-based support. Once approved, LUVENIQ would be the only uveitis therapy so rated and thus, one that should always be offered," Dr. Foster stated in his presentation to the AUS on Sunday October 25 at 8:00 pm PT.

Treatment with LX211 was overall well tolerated at the twice-daily 0.4 mg/kg dose, demonstrating a safety profile that appears suitable for chronic use. Adverse effects on renal function (8.2% of subjects with decrease from baseline of ≥30% in glomerular filtration rate vs. 4.1 % in placebo) and blood pressure (mean increase in systolic BP by 6 mm Hg) were moder
'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Peregrines PS-targeting antibodies highlighted in AACR Annual Meeting studies
2. Agricultural research highlighted in Houston
3. Heat forms potentially harmful substance in high-fructose corn syrup
4. Iowa State University researcher uncovers potential key to curing tuberculosis
5. Mechanism for potential Friedreichs ataxia drug uncovered
6. The vasculature emerges as a potential therapeutic target in treating ADPKD liver cysts
7. National new biology initiative offers potential for remarkable and far-reaching benefits
8. Fear of insurance rejection deters potentially life saving genetic tests for bowel cancer
9. Time to tap climate change-combating potential of the worlds ecosystems
10. Time to tap climate-change-combating potential of the worlds ecosystems
11. UCSB scientists discover potential drug delivery system
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces the second ... is underway to early access pre-order customers. ... at retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, ... was accepted at all outlets and very easy to ...
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
(Date:3/30/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) ... Recognition Market in Automotive Sector 2014-2018" report to ... Gesture Recognition market in Automotive Sector to grow at ... Gesture recognition is the ability of a device ... individual. Gesture recognition technology can be 2D-based or 3D-based. ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... April 11, 2011 (BRONX, NY) Just as inhaling ... it. Two researchers at Albert Einstein College of Medicine ... grant from the National Institutes of Health to clinically develop ... before the cancer becomes malignant and spreads. The grant ...
... SEATTLE, Wash.April 12, 2011The Allen Institute for Brain ... genomically comprehensive human brain map, a previously unthinkable ... than four years of rigorous studies and documentation. ... Allen Human Brain Atlas, an online public resource ...
... material available to identify persons or find next of kin ... the kits usually employed to carry out DNA identifications do ... is not available, and that which is available is highly ... persons from these small fragments of DNA. His thesis, presented ...
Cached Biology News:NIH funds investigation of inhaled lung cancer treatment 2Allen Institute for Brain Science announces first comprehensive gene map of the human brain 2Allen Institute for Brain Science announces first comprehensive gene map of the human brain 3Developing a tool for identification -- even using very degraded DNA samples 2Developing a tool for identification -- even using very degraded DNA samples 3
(Date:5/4/2015)... 4, 2015  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... address unmet medical needs in the areas of inflammation, ... presenting preclinical data from three of its biodefense programs ... Technology Conference on May 12-14, 2015 to be held ... Plaza, St. Louis MO 63101. ...
(Date:5/4/2015)... 2015   Sentrian ™, the Remote Patient Intelligence™ ... the Scripps Translational Science Institute (STSI) to ... with chronic obstructive pulmonary disease (COPD), a chronic condition ... nation,s third leading cause of death. The patients are ... , a wholly owned subsidiary of Anthem.   ...
(Date:5/1/2015)... , May 1, 2015 Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its first quarter 2015 financial results ... before the open of market. At 8:30 am Eastern ... to discuss the financial results and provide a ...
(Date:5/1/2015)... May 1, 2015 According ... Market by Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), ... Labs, Research Institutes) - Analysis & Global Forecast ... the global Antibody Production Market for the forecast ... expected to reach $2.572 Billion by 2019 from ...
Breaking Biology Technology:Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 2CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 4CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 5Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4
... , VANCOUVER , June 28 /PRNewswire-FirstCall/ - Dragon ... announced that its Special Meeting of Shareholders will be held on ... Time at the Company,s corporate office located at Suite 310, ... 4N9. Only shareholders of record of as of May 28, ...
... 28 Abviva, Inc. (OTC: ABVV), a biomedical company engaged ... Mammastatin, today announced they will be presenting at OneMedForum sponsored by ... 2010. Stifel was recently ranked #1 overall out of 183 qualifying ... on the Street Survey for 2010 . , ...
... ,, CHENNAI, India , June 28, 2010 ... an order worth USD 6 million from the private organizations and,Government ... Kenya , Tanzania and Ethiopia . The company will be ... , , ...
Cached Biology Technology:Dragon Pharma announces date of special meeting 2Abviva to Present at OneMedForum Sponsored by Stifel Nicolaus 2Indian Multinational Company Confirms USD 6 Million Order to Set up Industrial Waste Water Treatment Plants in Africa 2Indian Multinational Company Confirms USD 6 Million Order to Set up Industrial Waste Water Treatment Plants in Africa 3
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Prepared from plasminogen by activation with immobilized human uPA...
Human FADD Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
Biology Products: